




# PHARMACEUTICAL 2018

## LIXTE BIOTECHNOLOGY HOLDINGS INC.

Rank 255 of 342





# PHARMACEUTICAL 2018

## LIXTE BIOTECHNOLOGY HOLDINGS INC. Rank 255 of 342

The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Net Income, reducing the Economic Capital Ratio by 117% points.

The company's Economic Capital Ratio, given in the ranking table, is -11%, being 57% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	1,368
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	373
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1.4
Other Revenues	0
Property and Equipment	0
Research and Development	467
Selling, General and Administrative Expense	1,343

Output Variable	Value in 1000 USD
Assets	1,368
Liabilities	373
Expenses	1,810
Revenues	0
Stockholders Equity	995
Net Income	-1,808
Comprehensive Net Income	-1,808
Economic Capital Ratio	-11%